Diamyd Medical AB lost around 40 percent of its value Monday on news that it had to jettison a Phase II/III clinical trial of Diamyd, a therapeutic vaccine in development for treating autoimmune diabetes.(BioWorld International)

Bavarian Nordic A/S could earn a total of $1.6 billion from its contract with the U.S. Department of Health and Human Services to supply a stockpile of next-generation safe smallpox vaccines. (BioWorld International)

Bavarian Nordic A/S could earn a total of $1.6 billion from its contract with the U.S. Department of Health and Human Services to supply a stockpile of next-generation safe smallpox vaccines. (BioWorld International)